Cyclophosphamide Versus Mycophenolate Mofetil for Initial Treatment of Lupus Nephritis

Kidney International - United States
doi 10.1038/ki.2013.20
Full Text
Abstract

Available in full text

Categories
Nephrology
Date
Authors
Publisher

Elsevier BV

Related search

Outcomes Following Mycophenolate Mofetil Versus Cyclophosphamide Induction Treatment for Proliferative Juvenile-Onset Lupus Nephritis

Lupus
Rheumatology
2019English

Comparative Effectiveness of Mycophenolate Mofetil for the Treatment of Childhood-Onset Proliferative Lupus Nephritis

Arthritis Care and Research
Rheumatology
2017English

Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis With Poor Kidney Function: A Subgroup Analysis of the Aspreva Lupus Management Study

American Journal of Kidney Diseases
Nephrology
2013English

Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2007English

81 Outcomes of Multi-Target Therapy Using Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis

2017English

Efficacy of High-Dose Mycophenolate Mofetil in Multitarget Therapy for Lupus Nephritis: Two Consecutive Case Reports

Cureus
2020English

Randomised Trial of Mycophenolate Mofetil Versus Azathioprine for Treatment of Chronic Active Crohnʼs Disease

European Journal of Gastroenterology and Hepatology
HepatologyGastroenterology
1999English

Leflunomide Versus Cyclophosphamide in the Induction Treatment of Proliferative Lupus Nephritis in Chinese Patients: A Randomized Trial

Clinical Rheumatology
MedicineRheumatology
2018English

Mycophenolate Mofetil Reduces STAT3 Phosphorylation in Systemic Lupus Erythematosus Patients

JCI insight
Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy